Our Work
Latham Advises on Lyell Immunopharma’s US$80 Million Private Placement
November 5, 2026
Firm represents the placement agents in the transaction by the late-stage clinical company to advance ronde-cel toward planned BLA submission.
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, has announced that it has entered into a securities purchase agreement for a private placement of approximately US$80 million of its common stock. The investors include ARCH Venture Partners, Adage Capital Management LP, Caligan Partners LP, RTW Investments, a leading mutual fund, and other new and existing institutional investors.
Latham & Watkins LLP represents the placement agents in the transaction with a corporate team led by San Diego partner Matt Bush and counsel Anthony Gostanian, with associate Sterling Swift and assistance from Maria Watters.